1350 GMT - Roche Holding provided an encouraging update on its plans for a new breast-cancer drug, which together with other upcoming product launches underscore the company's confidence in its growth through the end of the decade, Citi analysts say. The Swiss drugmaker signaled it is comfortable with 2027 consensus estimates for sales of its breast-cancer drug, giredestrant, of 600 million Swiss francs, Citi says in a research note. Roche plans a patient-assistance program, offering the drug for free to some patients initially to reduce access barriers with the hope of seeing a "hockey-stick" launch trajectory, the analysts say. Citi expects the sales impact to be covered by 2028, and reiterates its forecast of annual peak sales of $14.5 billion. Shares fall 1.2%.